Hims & Hers Health faces lawsuit over alleged deceptive promotion of Wegovy knockoffs.

Hims & Hers Health shareholders who purchased shares between April 29, 2025, and June 23, 2025, are encouraged to contact Gross Law Firm regarding possible lead plaintiff appointment. The complaint alleges that Hims engaged in deceptive promotion and selling of illegitimate versions of Wegovy, putting patient safety at risk and posing a substantial risk to the company's collaboration with Novo Nordisk.

Hims & Hers Health, Inc. (NYSE: HIMS) shareholders who purchased shares between April 29, 2025, and June 23, 2025, are encouraged to contact the Gross Law Firm regarding possible lead plaintiff appointment in a class action lawsuit. The complaint alleges that Hims engaged in deceptive promotion and selling of illegitimate versions of Wegovy, putting patient safety at risk and posing a substantial risk to the company's collaboration with Novo Nordisk.

The Gross Law Firm has issued a notice to shareholders, stating that the complaint alleges that during the specified class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that Hims was engaged in the "deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk." Additionally, the complaint alleges that there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated as a result of these actions, and that Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis [1].

The deadline for shareholders to register for this class action is August 25, 2025. Once registered, shareholders will be enrolled in a portfolio monitoring software to receive status updates throughout the case. The Gross Law Firm is a nationally recognized class action law firm committed to protecting the rights of investors who have suffered losses due to deceit, fraud, and illegal business practices [2].

Faruqi & Faruqi, LLP, another leading national securities law firm, is also investigating potential claims against Hims & Hers Health, Inc. and encourages investors who suffered losses exceeding $50,000 to contact them directly to discuss their options. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995 [3].

On June 23, 2025, Novo Nordisk announced that it was ending its partnership with Hims, stating that Hims "has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization’ and are disseminating deceptive marketing that put patient safety at risk." This news led to a significant drop in Hims' stock price, injuring investors [3].

Shareholders should not delay in registering for this class action. Register your information here: [https://securitiesclasslaw.com/securities/hims-hers-health-inc-loss-submission-form/?id=158790&from=4] [1].

References:
[1] https://www.prnewswire.com/news-releases/hims--hers-health-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-before-august-25-2025-to-discuss-your-rights--hims-302518193.html
[2] https://www.marketscreener.com/news/hims-hers-health-inc-securities-fraud-class-action-lawsuit-pending-contact-the-gross-law-firm-b-ce7c5fddda80f726
[3] https://www.globenewswire.com/news-release/2025/07/30/3124586/683/en/SHAREHOLDER-NOTICE-Faruqi-Faruqi-LLP-Investigates-Claims-on-Behalf-of-Investors-of-Hims-Hers-Health.html